Search details
1.
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Cancer
; 121(3): 448-56, 2015 Feb 01.
Article
in English
| MEDLINE | ID: mdl-25273224
2.
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
JAMA
; 311(19): 1998-2006, 2014 May 21.
Article
in English
| MEDLINE | ID: mdl-24846037
3.
Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance.
Appl Immunohistochem Mol Morphol
; 28(9): 669-677, 2020 10.
Article
in English
| MEDLINE | ID: mdl-31876606
4.
The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).
Clin Cancer Res
; 24(5): 1038-1047, 2018 03 01.
Article
in English
| MEDLINE | ID: mdl-29217530
5.
Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.
J Thorac Oncol
; 10(5): 768-777, 2015 May.
Article
in English
| MEDLINE | ID: mdl-25738220
Results
1 -
5
de 5
1
Next >
>>